产品号 #60132_C
Mouse monoclonal IgG1 antibody against rhesus red blood cells
概述
The mouse monoclonal antibody T3G6 recognizes mature red blood cells and erythroid precursor cells in rhesus monkey bone marrow. Antibody clone T3G6 has been developed in mice immunized with rhesus monkey (Macaca mulatta) red blood cells. The antigen to which clone T3G6 binds has not been identified. The reactivity with red blood cells from other monkey species has not been determined. Clone T3G6 does not recognize human red blood cells.
Subtype
Primary Antibodies
Target Antigen
Red Blood Cell
Alternative Names
Erythrocyte, RBC
Reactive Species
Non-Human Primate
Conjugation
Unconjugated
Host Species
Mouse
Cell Type
Erythroid Cells, Red Blood Cells
Species
Non-Human Primate
Application
Cell Isolation, Flow Cytometry
Area of Interest
Immunology
Clone
T3G6
Gene ID
Not available
Isotype
IgG1, kappa
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (2)
Publications (1)
Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells. Journal of virology 2009 OCT
Abstract
Human immunodeficiency virus type 1 (HIV-1) vectors transduce rhesus blood cells poorly due to a species-specific block by TRIM5alpha and APOBEC3G, which target HIV-1 capsid and viral infectivity factor (Vif), respectively. We sought to develop a lentiviral vector capable of transducing both human and rhesus blood cells by combining components of both HIV-1 and simian immunodeficiency virus (SIV), including SIV capsid (sCA) and SIV Vif. A chimeric HIV-1 vector including sCA (chiHIV) was superior to the conventional SIV in transducing a human blood cell line and superior to the conventional HIV-1 vector in transducing a rhesus blood cell line. Among human CD34(+) hematopoietic stem cells (HSCs), the chiHIV and HIV-1 vectors showed similar transduction efficiencies; in rhesus CD34(+) HSCs, the chiHIV vector yielded superior transduction rates. In in vivo competitive repopulation experiments with two rhesus macaques, the chiHIV vector demonstrated superior marking levels over the conventional HIV-1 vector in all blood lineages (first rhesus, 15 to 30% versus 1 to 5%; second rhesus, 7 to 15% versus 0.5 to 2%, respectively) 3 to 7 months postinfusion. In summary, we have developed an HIV-1-based lentiviral vector system that should allow comprehensive preclinical testing of HIV-1-based therapeutic vectors in the rhesus macaque model with eventual clinical application.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
